Low-dose versus standard-dose bacille Calmette–Guérin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials
Purpose: Intravesical BCG (bacille Calmette–Guérin) instillation in patients with non-muscle-invasive bladder cancer decreases the risk for tumor recurrence and progression. After one BCG product was discontinued, a chronic global BCG shortage occurred. We focused on identifying a reduced dose of BC...
Main Authors: | Se Young Choi, Moon Soo Ha, Jung Hoon Kim, Byung Hoon Chi, Jin Wook Kim, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2022-03-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/pdf/10.4111/icu.20210340 |
Similar Items
-
Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette–Guérin
by: Jung Hoon Kim, et al.
Published: (2021-08-01) -
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
by: Zongren Wang, et al.
Published: (2018-11-01) -
Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01) -
Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
by: Lin PT, et al.
Published: (2022-11-01) -
Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)